Patrick Barnable
Overview
Explore the profile of Patrick Barnable including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ho K, Hoesley C, Anderson P, Fernandez-Romero J, Friedland B, Kelly C, et al.
J Acquir Immune Defic Syndr
. 2025 Jan;
97(4):379-386.
PMID: 39808074
Background: On demand, topical PrEP is desired by those preferring episodic, nonsystemic PrEP. PC-1005 gel (MIV-150, zinc, and carrageenan) exhibits in vitro antiviral HIV-1, human papillomavirus (HPV), and herpes simplex...
2.
Barnable P, Mukhopadhyay S, Kizima L, Kumar N, Plagianos M, Mehandru S, et al.
AIDS Res Hum Retroviruses
. 2023 Apr;
PMID: 37002886
The biology of HIV-1 acquisition through unprotected receptive anal intercourse is understudied. Considering that sex hormones are implicated in intestinal physiology, pathology, and HIV acquisition and pathogenesis, we explored links...
3.
Teleshova N, Keller M, Romero J, Friedland B, Creasy G, Plagianos M, et al.
PLoS One
. 2022 Jan;
17(1):e0261775.
PMID: 35051209
HIV pre-exposure prophylaxis (PrEP) is dominated by clinical therapeutic antiretroviral (ARV) drugs. Griffithsin (GRFT) is a non-ARV lectin with potent anti-HIV activity. GRFT's preclinical safety, lack of systemic absorption after...
4.
Calenda G, Villegas G, Reis A, Millen L, Barnable P, Mamkina L, et al.
AIDS Res Hum Retroviruses
. 2019 Jan;
35(3):335-347.
PMID: 30600686
Factors underlying HIV acquisition in women remain incompletely understood. This study evaluated ex vivo mucosal HIV-1 infection (ectocervix, endocervix), T cell frequencies and phenotype (ectocervix, endocervix, peripheral blood), and HIV-1-induced...
5.
Derby N, Lal M, Aravantinou M, Kizima L, Barnable P, Rodriguez A, et al.
Nat Commun
. 2018 Sep;
9(1):3881.
PMID: 30250170
Human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) strategies with proven in vivo efficacy rely on antiretroviral drugs, creating the potential for drug resistance and complicated treatment options in individuals who...
6.
Calenda G, Villegas G, Barnable P, Litterst C, Levendosky K, Gettie A, et al.
J Acquir Immune Defic Syndr
. 2016 Aug;
74(3):e67-e74.
PMID: 27552154
The Population Council's microbicide gel MZC (also known as PC-1005) containing MIV-150 and zinc acetate dihydrate (ZA) in carrageenan (CG) has shown promise as a broad-spectrum microbicide against HIV, herpes...
7.
Jean-Pierre N, Barnable P, Kizima L, Rodriguez A, Seidor S, Cooney M, et al.
Antimicrob Agents Chemother
. 2015 Nov;
60(2):1141-4.
PMID: 26596943
We compared the preclinical safety and efficacy of tenofovir (TFV) 1% gel with that of MZC gel [containing 50 μM MIV-150, 14 mM Zn(O2CCH3)2(H2O)2, and 3% carrageenan] through a series...
8.
Barnable P, Calenda G, Bonnaire T, Menon R, Levendosky K, Gettie A, et al.
Antimicrob Agents Chemother
. 2015 Apr;
59(7):3829-37.
PMID: 25870063
The transmission of both cell-free and cell-associated immunodeficiency viruses has been demonstrated directly in multiple animal species and possibly occurs in humans, as suggested by genotyping of the infecting human...
9.
Barnable P, Calenda G, Ouattara L, Gettie A, Blanchard J, Jean-Pierre N, et al.
PLoS One
. 2014 Sep;
9(9):e108109.
PMID: 25259616
To extend our observations that single or repeated application of a gel containing the NNRTI MIV-150 (M) and zinc acetate dihydrate (ZA) in carrageenan (CG) (MZC) inhibits vaginal transmission of...
10.
Ouattara L, Barnable P, Mawson P, Seidor S, Zydowsky T, Kizima L, et al.
Antimicrob Agents Chemother
. 2014 Mar;
58(5):2841-8.
PMID: 24614384
Recent studies demonstrated that intravaginal rings (IVRs) containing 100 mg of the nonnucleoside reverse transcriptase inhibitor (NNRTI) MIV-150 significantly protect macaques against a chimeric simian-human immunodeficiency virus that expresses the...